Study of Talazoparib, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors

Phase 1

Completed

• Conditions: Advanced or Recurrent Solid Tumors; Breast Neoplasms; Ovarian Cancer, Epithelial; Ewing Sarcoma; Small Cell Lung Carcinoma; Prostate Cancer; Pancreas Cancer
• Interventions: Drug: Talazoparib

• Registration Number: NCT01286987
• Lead Sponsor: Pfizer

Brief Summary

This is a single-arm, open-label study to assess the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of talazoparib in patients with advanced tumors with DNA-repair pathway deficiencies. There will be 2 parts to the study: a dose escalation phase in which the maximum tolerated dose will be defined, and a dose expansion phase.

Detailed Description

Not available

Study Timeline

• Study Start: 2011-01-03
• Study First Submitted: 2011-01-26
• Study First Submitted QC: 2011-01-28
• Study First Posted: 2011-02-01
• Primary Completion: 2015-03-31
• Study Completion: 2017-01-30
• Results First Submitted: 2018-01-31
• Status Verified: 2018-06
• Results First Submitted QC: 2018-06-29
• Last Update Submitted: 2018-06-29
• Results First Posted: 2019-01-10
• Last Update Posted: 2019-01-10

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 113

Inclusion Criteria

• Histologically or cytologically documented, unresectable, locally advanced or metastatic solid tumor
• Must have available archived tumor tissue (formalin-fixed paraffin-embedded) [FFPE].
• 18 years of age or older.
• Have measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST, v1.1) or increased CA-125 (ovarian cancer) or PSA (prostate cancer) and/or CA 19-9 (pancreatic cancer).
• Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1.
• Have adequate organ function
• Able to take oral medications.
• Willing and able to provide informed consent.
• Sexually active patients must be willing to use an acceptable method of contraception.
• Females of childbearing potential must have a negative serum pregnancy test at screening.
• Willing and able to comply with all study procedures.

Part 2 Dose Expansion Tumor Types:

• Breast and ovarian cancer patients with deleterious or pathogenic BRCA mutations who have received no more than 4 prior regimens for metastatic disease.
• Prostate or pancreatic cancer patients with deleterious or pathogenic BRCA mutations who have received no more than 2 prior regimens for metastatic disease.
• Small cell lung cancer (SCLC) patients who have received no more than one prior regimen for SCLC.
• Ewing's sarcoma patients who have received no more than 3 prior regimens for metastatic disease.

Exclusion Criteria

• Part 2 Expansion: Prior treatment with a PARP inhibitor.

• Has history of central nervous system (CNS) metastasis.

  * Exception: In patients with SCLC, history of adequately treated brain metastasis who do not require corticosteroids for management of CNS symptoms.

• Has had major surgery within 28 days before Cycle 1, Day 1.

• Has active peptic ulcer disease.

• Active gastrointestinal tract disease with malabsorption syndrome.

• Pregnant or breastfeeding at screening or planning to become pregnant (in each case, either oneself or one's partner) at any time during the study.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Talazoparib	Talazoparib	-

Primary Outcome Measures

Name	Time	Method
Number of Participants With Best Overall Response	From Baseline until disease progression or death due to any cause (maximum duration: 1071 days for Part 1; 834 days for Part 2)	Best overall response: best response (in the order of confirmed CR, confirmed PR, stable disease \[SD\] and progressive disease \[PD\]) among all overall response as RECIST 1.1, recorded from date of first dose of talazoparib until participant withdrew from study/data cut-off date, whichever earlier. CR defined as disappearance of all non-nodal target lesions (where all target lesions recorded with a length of 0 mm on the CRF) and the reduction of the shortest diameter of all nodal lesions to \< 10 mm. PR defined as at least a 30% decrease in sum of the diameters of target lesions, reference to baseline sum diameters. SD defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study. PD defined as at least a 20% increase in sum of diameters of target lesions, reference to the smallest sum on study (this includes the baseline sum if that was the smallest on study).
Number of Participants With Objective Response	From Baseline until disease progression or death due to any cause (maximum duration: 1071 days for Part 1; 834 days for Part 2)	Objective response in participants was defined as the number of participants with complete response (CR) or partial response (PR) after treatment with talazoparib and maintained for at least 4 weeks (28 days) as assessed by response evaluation criteria in solid tumors (RECIST) version 1.1. CR defined as disappearance of all non-nodal target lesions (where all target lesions were recorded with a length of 0 millimeter \[mm\] on the case report form \[CRF\]) and the reduction of the shortest diameter of all nodal lesions to less than \[\<\] 10 mm. PR was defined by a 30% or more decrease in the sum of the longest diameters (SLD) + sum of shortest diameters (SSD) of target lesions, taking as reference the baseline SLD+SSD.
Progression-Free Survival (PFS)	Baseline, until PD or death due to any cause (maximum duration:1071 days for Part 1; 834 days for Part 2)	PFS was defined as the time (in weeks) from the date of first dose of study drug to the earlier date of the documented PD or death due to any cause. PD as per RECIST 1.1 defined as at least a 20% increase in the sum of diameters of target lesions, reference to the smallest sum on study (this includes the baseline sum if that was the smallest on study).
Duration of Response	Baseline until PD or death due to any cause (maximum duration: 1071 days for Part 1; 834 days for Part 2)	Duration of response was defined as the time (in weeks) from the date of the first documented objective response confirmed at least 28 days later to the date of the first documented PD or date of death, whichever occurred first. PD as per RECIST version 1.1 defined as at least a 20% increase in the sum of diameters of target lesions, reference to the smallest sum on study (this includes the baseline sum if that was the smallest on study).
Number of Participants With Stable Disease	Baseline, until PD or death due to any cause (maximum duration: 1071 days for Part 1; 834 days for Part 2)	SD defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study. PD defined as at least a 20% increase in sum of diameters of target lesions, reference to the smallest sum on study (this includes the baseline sum if that was the smallest on study).
Part 1: Maximum Tolerated Dose (MTD)	Cycle 1 (Day 1 up to Day 42)	The MTD was defined as the highest dose at which no more than 1 of 6 participants experienced a Dose Limiting Toxicity (DLT). DLT defined as any of the following occurring during cycle 1 of part 1 of study, Hematologic toxicity: Any grade 4 or higher hematologic adverse event, Grade 3 thrombocytopenia associated with grade 2 or higher haemorrhage, Grade 3 thrombocytopenia or neutropenia that led to interruption of dosing for 5 or more days. Nonhematologic toxicity: grade 3 or higher laboratory AE which was asymptomatic and rapidly reversible adverse events (returned to baseline or to grade 1 or lower within 7 days), Grade 3 nausea, vomiting, or diarrhea that could be medically managed to grade 2 or lower with anti-emetics and/or anti-diarrheals within 24 hours, Grade 3 fatigue that improved to grade 2 or lower in 5 days or less, Alopecia. Grades based on National Cancer Institute Common Terminology Criteria for Adverse Events version 4.03.
Part 1: Recommended Part 2 Dose of Talazoparib	Baseline up to Cycle 50 (each cycle 28 days)	The Recommended dose of talazoparib for use in Part 2 was determined in Part 1 (dose escalation) on the basis of the totality of safety, pharmacokinetics (PK), pharmacodynamic and preliminary efficacy data observed in Cycles 1 and 2 and beyond.

Trial Locations

Locations (15)

Ronald Reagan UCLA Medical Center; 🇺🇸 Los Angeles, California, United States

UCLA Hematology/Oncology; 🇺🇸 Los Angeles, California, United States

Santa Monica - UCLA Medical Center & Orthopaedic Hospital; 🇺🇸 Santa Monica, California, United States

UCLA Hematology/Oncology - Santa Monica; 🇺🇸 Santa Monica, California, United States

IU Health University Hospital; 🇺🇸 Indianapolis, Indiana, United States

Scottsdale Healthcare; 🇺🇸 Scottsdale, Arizona, United States

Virginia G. Piper Cancer Center Research Pharmacy; 🇺🇸 Scottsdale, Arizona, United States

(IRB# 12-000131) Ronald Reagan UCLA Medical Center, Drug Information Center; 🇺🇸 Los Angeles, California, United States

Westwood Bowyer Clinic, Peter Morton Medical Building; 🇺🇸 Los Angeles, California, United States

Investigational Drug Services; 🇺🇸 Indianapolis, Indiana, United States

IU Health Bloomington Hospital; 🇺🇸 Bloomington, Indiana, United States

The University of Texas MD Anderson Cancer Center; 🇺🇸 Houston, Texas, United States

Indiana University Health Melvin and Bren Simon Cancer Center; 🇺🇸 Indianapolis, Indiana, United States

University of Michigan Health System; 🇺🇸 Ann Arbor, Michigan, United States

Royal Marsden Hospital NHS Foundation Trust; 🇬🇧 Sutton, Surrey, United Kingdom